alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.1630 Oxfendazole suspension. ( a ) *Specifications.* Each milliliter of suspension contains: ( 1 ) 90.6 milligrams (mg) oxfendazole (9.06 percent).
( 2 ) 225.0 mg oxfendazole (22.5 percent).
( b ) *Sponsor.* See Nos. 000010 and 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances. See* § 556.495 of this chapter.
( d ) *Special considerations.* See § 500.25 of this chapter. If labeled for administration by stomach tube: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( e ) *Conditions of use* — ( 1 ) *Horses.* Use the product described in paragraph (a)(1) of this section as follows: ( i ) *Amount.* 10 mg per kilogram (/kg) of body weight by stomach tube or dose syringe. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks.
( ii ) *Indications for use.* For removal of large roundworms (*Parascaris equorum*), mature and 4th stage larvae pinworms (*Oxyuris equi*), large strongyles (*Strongylus edentatus, S. vulgaris,* and *S. equinus*), and small strongyles.
( iii ) *Limitations.* Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Do not use in horses intended for human consumption.
( 2 ) *Cattle.* Use the products described in paragraphs (a)(1) and (a)(2) of this section as follows: ( i ) *Amount.* 4.5 mg/kg of body weight by dose syringe. Treatment may be repeated in 4 to 6 weeks.
( ii ) *Indications for use.* For the removal and control of: lungworms (*Dictyocaulus viviparus*—adult, L4); stomach worms: barberpole worms (*Haemonchus contortus* and *H. placei*—adult), small stomach worms (*Trichostrongylus axei*—adult), brown stomach worms (*Ostertagia ostertagi*—adult, L4, inhibited L4); intestinal worms; nodular worms (*Oesophagostomum radiatum*—adult), hookworms (*Bunostomum phlebotomum*—adult), small intestinal worms (*Cooperia punctata, C. oncophora,* and *C. surnabada*—adult, L4), and tapeworms (*Moniezia benedeni*—adult).
( iii ) *Limitations.* Cattle must not be slaughtered until 7 days after treatment. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age.
[55 FR 46943, Nov. 8, 1990, as amended at 56 FR 8710, Mar. 1, 1991; 61 FR 5506, Feb. 13, 1996; 72 FR 10596, Mar. 9, 2007; 73 FR 45610, Aug. 6, 2008; 75 FR 10166, Mar. 5, 2010; 78 FR 28825, May 20, 2014]
§ 582.6195 Calcium citrate. ( a ) *Product.* Calcium citrate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1091 Succinic acid. ( a ) Succinic acid (C4H6O4, CAS Reg. No. 110-15-6), also referred to as amber acid and ethylenesuccinic acid, is the chemical 1,4-butanedioic acid. It is commercially prepared by hydrogenation of maleic or fumaric acid. It can also be produced by aqueous alkali or acid hydrolysis of succinonitrile.
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), pp. 314-315, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as a flavor enhancer as defined in § 170.3(o)(11) of this chapter and pH control agent as defined in § 170.3(o)(23) of this chapter.
( d ) The ingredient is used in food at levels not to exceed good manufacturing practice in accordance with § 184.1(b)(1). Current good manufacturing practice results in a maximum level, as served, of 0.084 percent in condiments and relishes as defined in § 170.3(n)(8) of this chapter and 0.0061 percent in meat products as defined in § 170.3(n)(29) of this chapter.
( e ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[44 FR 20657, Apr. 6, 1979, as amended at 49 FR 5611, Feb. 14, 1984]
§ 510.203 Initiation of a proceeding to establish or amend an import tolerance. ( a ) Any interested person may request that the Commissioner establish or amend an import tolerance. Such a request must be in the form specified in § 510.205 of this chapter.
( b ) The Commissioner may initiate a proceeding to establish or amend an import tolerance on his or her own initiative pursuant to § 10.25(b) of this chapter.
§ 582.3149 Ascorbyl palmitate. ( a ) *Product.* Ascorbyl palmitate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<PAGE>   1

                                                                   EXHIBIT 11.1

COMPUTATION OF EARNINGS (LOSS) PER SHARE



<TABLE>
<CAPTION>
                                                 THREE MONTHS ENDED                  SIX MONTHS ENDED
                                                      June 30,                            June 30,
                                            ------------------------------      ------------------------------
                                                1999              1998              1999              1998
                                            ------------      ------------      ------------      ------------
<S>                                          <C>               <C>               <C>               <C>
PRIMARY AND FULLY DILUTED:

Average shares outstanding                    17,489,812        15,685,267        17,201,618        15,630,814

Effect of dilutive stock options               1,953,433         2,037,265                --         2,037,265

Effect of shares over market                  (1,291,233)         (472,500)               --          (472,500)
                                            ------------      ------------      ------------      ------------

Total                                         18,152,012        17,250,032        17,201,618        17,195,579
                                            ============      ============      ============      ============

Net earnings (loss)                         $     44,168      $      5,198      $   (278,491)     $    105,692
                                            ============      ============      ============      ============

Primary net earnings (loss) per share       $      0.003      $      0.000      $     (0.016)     $      0.007
                                            ============      ============      ============      ============

Fully diluted earnings per share            $      0.002      $      0.000                        $      0.006
                                            ============      ============                        ============
</TABLE>



                                       14
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                              JAN-1-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                       4,629,234
<SECURITIES>                                 6,328,146
<RECEIVABLES>                               32,825,351
<ALLOWANCES>                               (1,146,051)
<INVENTORY>                                 39,678,922
<CURRENT-ASSETS>                            86,636,679
<PP&E>                                      35,713,045
<DEPRECIATION>                            (15,211,290)
<TOTAL-ASSETS>                             120,853,879
<CURRENT-LIABILITIES>                       49,378,991
<BONDS>                                     15,664,662
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    25,802,401
<OTHER-SE>                                  24,504,581
<TOTAL-LIABILITY-AND-EQUITY>               120,853,879
<SALES>                                    153,822,022
<TOTAL-REVENUES>                           153,822,022
<CGS>                                       96,719,936
<TOTAL-COSTS>                               96,719,936
<OTHER-EXPENSES>                            48,926,567
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                         (2,772,243)
<INCOME-PRETAX>                              6,068,048
<INCOME-TAX>                               (2,810,781)
<INCOME-CONTINUING>                          3,257,267
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 3,257,267
<EPS-BASIC>                                       0.27
<EPS-DILUTED>                                     0.27


</TABLE>
IN THE SUPREME COURT OF THE STATE OF DELAWARE

JAMES ST. LOUIS

,

Defendant Below,

Appellant,

v.

STATE OF DELAWARE

,

Plaintiff Below,

Appellee. §

§

§ No. 1 60 , 2019

§

§ Court Below

— Superior Court

§ of the State of Delaware

§

§ Cr. ID No. 00 0 9015005 (S)

§

§

§

Submitted: June 13, 2019

Decided: June 18 , 2019

ORDER

Following the denial of his motion to proceed in forma pauperis on May 28

,

2019 , the appellant was directed to pay the Court’s filing fee by June 12, 2019 , or

else his appeal would be dismissed without further notice. The appellant has not

paid the filing fee. The dismissal of this appeal is therefore deemed to be unopposed.

NOW, THEREFORE, IT IS ORDERED, under Supreme Court Rule s 3(b)(2)

and 29 (b) , that this petition is DISMISSED.

BY THE COURT:

/s/ Karen L. Valihura

Justice
## NO. 12

- 10

- 00 33 4

- C R

IN THE COURT OF APPEALS

TWELFTH COURT OF APPEALS DISTRICT

TYLER, TEXAS

MICHAEL KENNEDY, § APPEAL FROM THE THIRD APPELLANT

V. § JUDICIAL DISTRICT COURT OF
THE STATE OF TEXAS, APPELLEE § ANDERSON COUNTY, TEXAS

MEMORANDUM OPINION PER CURIAM Appellant Michael Kennedy was convicted of burglary of a building for which sentence was imposed on September 16, 1986. This court affirmed the conviction, s ee Kennedy v. State
, No. 12

- 86

- 00248

- CR (T ex. App.

– Tyler Feb. 25, 1988, no pet.) (not designated for publication), and issued its mandate on April 13, 1988. On October 4, 2010, Appellant filed a notice of appeal seeking relief from the final judgment. On October 8, 2010, this court notified App ellant, pursuant to Texas Rule of Appellate Procedure 37.2, that the information received in this appeal does not contain a final judgment or other appealable order. Appellant was further informed that the appeal would be dismissed if the
information rece ived in the appeal was not amended on or before November 8, 2010, to show the jurisdiction of this court. In response to this court’s notice, Appellant filed a motion requesting an additional forty

- five days to provide a final judgment or other appealable order. After considering Appellant’s motion and the procedural history of the underlying case, Appellant’s motion for extension of time is overruled, and the appeal is dismissed for want of jurisdiction

. See T EX

. R. A PP

. P. 37.1, 42.3. All pending mot ions are overruled as moot. Opinion delivered November 10, 2010. Panel consisted of Worthen, C.J., Griffith, J., and Hoyle, J. (DO NOT PUBLISH)
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               DEC-28-1997
<CASH>                                          41,046
<SECURITIES>                                         0
<RECEIVABLES>                                  574,825
<ALLOWANCES>                                    36,006
<INVENTORY>                                    555,593
<CURRENT-ASSETS>                             1,183,716
<PP&E>                                         869,661
<DEPRECIATION>                                 300,621
<TOTAL-ASSETS>                               2,479,898
<CURRENT-LIABILITIES>                          610,601
<BONDS>                                      1,223,140
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           213
<OTHER-SE>                                     344,757
<TOTAL-LIABILITY-AND-EQUITY>                 2,479,898
<SALES>                                      1,734,469
<TOTAL-REVENUES>                             1,734,469
<CGS>                                        1,272,100
<TOTAL-COSTS>                                1,272,100
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   430
<INTEREST-EXPENSE>                              86,016
<INCOME-PRETAX>                                 44,885
<INCOME-TAX>                                    21,240
<INCOME-CONTINUING>                             23,759
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                 17,094
<CHANGES>                                            0
<NET-INCOME>                                     6,665
<EPS-PRIMARY>                                     0.32
<EPS-DILUTED>                                     0.31
        

</TABLE>
#### §§ 250.106-250.107 [Reserved]
**Exhibit
23.1**
 
 **CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**
 
 Board of
Directors and Stockholders
 First
Mariner Bancorp
 Baltimore,
Maryland
 
 
 We
consent to the incorporation by reference in the Registration Statements (Nos.
333-60961, 333-60963, 333-60967, 333-107669, 333-114073 and 333-122464) on Form
S-8 (No. 333-107670) on Form S-3 and (No. 333-67854) on Form S-2 of First
Mariner Bancorp of our report dated April 11, 2005, with respect to First
Mariner Bancorp management’s assessment of the effectiveness of internal control
over financial reporting, and the effectiveness of internal control over
financial reporting, which report is included in this amended annual report on
Form 10-K/A of First Mariner Bancorp for the year ended December 31,
2004.
 
 /s/
Stegman & Company
 
 
 
 Baltimore,
Maryland
 April 27,
2005
# C_2014439EN.01002501.xml

| 8.12.2014 | EN | Official Journal of the European Union | C 439/25 |
| --- | --- | --- | --- |

8.12.2014

EN

Official Journal of the European Union

C 439/25

---

Action brought on 13 October 2014 — European Commission v Kingdom of Denmark

(Case C-468/14)

(2014/C 439/34)

Language of the case: Danish

Parties

Parties

Applicant: European Commission (represented by: M. Clausen. C. Cattabriga, acting as Agents)

Applicant:

Defendant: Kingdom of Denmark

Defendant:

Form of order sought

Form of order sought

| — | Declare that, by maintaining a legal situation in which the sale of loose snuff is permitted contrary to Article 8, read in conjunction with Article 2(4) of Directive 2001/37/EC of the European Parliament and of the Council of 5 June 2001 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco products (1), the Kingdom of Denmark has failed to fulfil its obligations under that directive; |
| --- | --- |

—

Declare that, by maintaining a legal situation in which the sale of loose snuff is permitted contrary to Article 8, read in conjunction with Article 2(4) of Directive 2001/37/EC of the European Parliament and of the Council of 5 June 2001 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco products (1), the Kingdom of Denmark has failed to fulfil its obligations under that directive;

1

| — | the order Kingdom of Denmark to pay the costs. |
| --- | --- |

—

the order Kingdom of Denmark to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The Kingdom of Denmark has failed to fulfil its obligations under Article 8 of Directive 2001/37/EC by prohibiting only sales of snuff in porous portion sachets, but not loose snuff, in Denmark. Denmark has not disputed that its national rules do not comply with EU law in so far as regards the prohibition of marketing of tobacco for oral use. A legislative proposal which would have introduced a complete prohibition on the sale of snuff in Denmark was, however, rejected by the Danish Parliament (Folketing).

Denmark has not given any further commitments that it will bring Danish rules into line with EU law. The Commission must accordingly conclude that Denmark has still failed to fulfil its obligations under Article 8 of the Directive, read in conjunction with Article 2(4) thereof.

---

(1)  OJ 2001 L 194, p. 26.

1

---
§ 1306.12 Refilling prescriptions; issuance of multiple prescriptions. ( a ) The refilling of a prescription for a controlled substance listed in Schedule II is prohibited.
( b ) ( 1 ) An individual practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply of a Schedule II controlled substance provided the following conditions are met: ( i ) Each separate prescription is issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice;
( ii ) The individual practitioner provides written instructions on each prescription (other than the first prescription, if the prescribing practitioner intends for that prescription to be filled immediately) indicating the earliest date on which a pharmacy may fill each prescription;
( iii ) The individual practitioner concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse;
( iv ) The issuance of multiple prescriptions as described in this section is permissible under the applicable state laws; and
( v ) The individual practitioner complies fully with all other applicable requirements under the Act and these regulations as well as any additional requirements under state law.
( 2 ) Nothing in this paragraph (b) shall be construed as mandating or encouraging individual practitioners to issue multiple prescriptions or to see their patients only once every 90 days when prescribing Schedule II controlled substances. Rather, individual practitioners must determine on their own, based on sound medical judgment, and in accordance with established medical standards, whether it is appropriate to issue multiple prescriptions and how often to see their patients when doing so.
[72 FR 64929, Nov. 19, 2007]
§ 582.6789 Tetra sodium pyrophosphate. ( a ) *Product.* Tetra sodium pyrophosphate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsAcoustic Directivity and Insertion Loss Measurements of Advanced Liners Installed the Inlet of the DGEN Aeropropulsion Research TurbofanThe NASA Glenn Research Center’s DGEN Aeropropulsion Research Turbofan (DART) is based on the Price Induction DGEN380—a small, ~500-lbf thrust class, high-bypass, geared-turbofan engine with a separate flow nozzle. The general characteristics of the DART make it an ideal candidate for utilization as a test bed for engine aeroacoustic research in a relevant performance environment. The DART was used to document the efficacy of acoustic liners installed in the inlet of the DGEN380. An advanced multi-degree-of-freedom liner (MDOF) was designed and tested, along with a traditional single-degree-of- freedom liner (SDOF), and those results compared to a hard-wall baseline inlet. Farfield acoustic data were acquired from an external array, evaluated, and reported here-in terms of overall, broadband, and tonal components of the insertion loss.Document ID20190011719Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsSutliff, Daniel L.*(NASA Glenn Research Center Cleveland, OH, United States)*Jones, Michael G.*(NASA Langley Research Center Hampton, VA, United States)*Nark, Douglas M.*(NASA Langley Research Center Hampton, VA, United States)*Date AcquiredMay 8, 2019Publication DateMay 1, 2019Subject CategoryAcousticsReport/Patent NumberE-19677NASA/TM-2019-220161Funding Number(s)WBS: 081876.02.03.50.03.06Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Technical ReviewSingle ExpertKeywordsNoise ReductionAcousticsAeroacousticsAvailable DownloadsNameType20190011719.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
H. R. 7606 

One Hundred Eighteenth Congress 

of the 

United States of America 

AT THE SECOND SESSION 

Begun and held at the City of Washington on Wednesday, 

the third day of January, two thousand and twenty-four 

An Act 

To designate the facility of the United States Postal Service located at 1087 Route 

47 South in Rio Grande, New Jersey, as the ‘‘Carlton H. Hand Post Office Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. CARLTON H. HAND POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 1087 Route 47 South in Rio Grande, New Jersey, 

shall be known and designated as the ‘‘Carlton H. Hand Post 

Office Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Carlton H. Hand Post Office Building’’. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.